Article
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2009
van Erp Nielka P, Eechoute Karel, van der Veldt Astrid A, Haanen John B, Reyners An K L, Mathijssen Ron H J, Boven Epie, van der Straaten Tahar, Baak-Pablo Renée F, Wessels Judith A M, Guchelaar Henk-Jan, Gelderblom Hans
Abstract excerpt
PURPOSE: To identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of sunitinib that predispose for development of toxicities: thrombocytopenia, leukopenia, mucosal inflammation, hand-foot syndrome, and any toxicity according to National Cancer Institute Common Toxicity Criteria higher than grade 2. PATIENTS AND METHODS: A multicenter pharmacogenetic association study was performed in 219...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
